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Japanese encephalitis virus (JEV) is a major cause of encephalitis in Asia, and the common-
est cause of mosquito-borne encephalitis worldwide. Detection of JEV RNA remains chal-
lenging due to the characteristic brief and low viraemia, with 0–25% of patients positive, and
the mainstay of diagnosis remains detection of anti-JEV IgM antibody.
Methods
We performed a systematic review of published RT-PCR protocols, and evaluated them in
silico and in vitro alongside new primers and probes designed using a multiple genome
alignment of all JEV strains >9,000nt from GenBank, downloaded from the NCBI website
(November 2016). The new assays included pan-genotype and genotype specific assays
targeting genotypes 1 and 3.
Results
Ten RT-qPCR assays were compared, a pre-existing in-house assay, three published
assays and six newly designed assays, using serial RNA dilutions. We selected three
assays, one published and two novel assays, with the lowest limit of detection (LOD) for fur-
ther optimisation and validation. One of the novel assays, detecting NS2A, showed the best
results, with LOD approximately 4 copies/ reaction, and no cross-reaction on testing closely
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Conclusions
We succeeded in developing a JEV specific RT-qPCR assay with at least 1 log10 improved
sensitivity as compared to existing assays. Further evaluation is required, field-testing the
assay in a larger group of patients.
Introduction
Japanese encephalitis virus (JEV) represents a major cause of encephalitis in Asia, with an esti-
mated 70,000 cases per year, and 20,000 deaths [1–5]. It is a highly neurotropic arthropod-
borne virus (arbovirus), a member of the genus Flavivirus and family Flaviviridae, and closely
related to West Nile virus (WNV) and St. Louis encephalitis virus (SLEV).
Five JEV genotypes have been identified, G1-5, with at least 12% nucleotide difference
between them, and concomitant geographical variations. G1 and G3 have been isolated and
characterised most extensively in humans [6–14]. G3 was the main genotype identified in Asia
until the 1990s. However, there has been a recognised genotype displacement to G1 which is
now predominant [10, 15]. G1 is the only genotype that has been isolated in Laos, but it is
likely that G3 co-circulates as well [6, 16].
JEV is transmitted between birds and swine in enzootic cycles with mosquito vectors
(mainly Culex spp.) [17]. Humans are ‘dead-end’ hosts, infected when they encroach upon
enzootic cycles, mainly involving transmission from swine, which live close to humans and
have high and prolonged viraemias. The viraemia elicited in humans is typically brief and low,
and in endemic areas only a small proportion of those infected (1 in 300) experience symptoms
[18–20].
There are recognised limitations in current diagnostics for JEV [21–24]. The mainstay of
diagnosis remains the detection of anti-JEV IgM antibody using IgM antibody capture ELISA
(JEV MAC-ELISA) from blood and/or cerebrospinal fluid (CSF) samples [25–27]. However
cross-reactivity of Flavivirus immune-assays is well-documented, as seen with Dengue virus
infection [28]. Moreover, recent dynamics in Flavivirus epidemiology, seen with the epidemic
of Zika virus, further questions our dependence on detection of anti-JEV IgM [28–31]. Field
studies suggest the sensitivity of JEV MAC-ELISA is only 50–93%, and more recently the posi-
tive predictive value has also been questioned [22, 23, 32, 33]. Additionally, the use of serology
for diagnostic confirmation limits knowledge of molecular epidemiology and vaccine efficacy.
Reasons for reliance on JEV MAC-ELISA are the short period of JEV viraemia in humans
and potential low sensitivity of existing JEV RT-PCR techniques. Data suggest that JEV RNA
is detected in blood and/or CSF in a very small proportion (0–25%) of clinical cases [32, 34].
Studies reporting higher proportions, 25–30%, involve selected patient populations, such as
patients with less than 3 days onset of fever and more severe symptoms [35, 36].
We aimed to perform a systematic review of the JEV RT-PCR assays available and to com-
pare their performance. In addition, we developed new assays, in order to obtain the highest
efficiency. This required extensive sequence analysis to design an in-silico optimal system fol-
lowed by optimization of the experimental protocol. A set of selected assays were then assessed
on patient samples.
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Material and methods
Systematic literature review
MEDLINE, EMBASE and Web of Science databases were searched for MESH and keywords
‘Japanese encephalitis’ and ‘Polymerase Chain Reaction or $ $ $PCR’ upto 31st January 2017.
References and citations of selected studies were also identified using Web of Science, and
hand-searched in bibliographies. Inclusion criteria involved English language studies report-
ing validation of RT-PCR methods for detection of JEV. Panflavivirus assays were not included
unless this was part of a multiplex including a specific probe for JEV.
Bioinformatic analysis, primer and probe design
JEV sequences over 9,000 nucleotides (nt) in length, identified in GenBank, were downloaded
in FASTA format from the NCBI website on 12th November 2016, and aligned using MAFFT
version 7 [37]. The pre-existing in-house assay (Unite´ des Virus Emergents, Marseille, 2014)
and published RT-qPCR assays were evaluated for best fit using the sequence alignment
uploaded to MEGA 7 [38]. New primers and probes were designed in areas with maximal con-
servation, with a GC clamp (one or more Gs or Cs within the last 5 bases from the 3’ end), Tm
of probes 10˚C higher than the primers, checking for hairpins, self-dimers, heterodimers using
the online IDTNA ‘oligoanalyzer tool’ 3.1 [39, 40]. The published and newly designed assays
included TaqMan1 Minor Groove Binder (MGB) probes. The sequences were also submitted
to nucleotide BLAST search on NCBI web server to ensure high specificity of the sequences for
JEV, and predicted products were folded using the M-fold web server to check for secondary
structures affecting the performance of the RT-qPCR [41, 42].
RNA standards
RNA from three JEV isolates were used for the optimisation process. Two G1 strains from
Laos, JEV/CNS1326/Laos/2013 (no titre available) and JEV/CNS769/Laos/2009 (1.3x106 RNA
copies/μl; GenBank KC196115, EVA 001V-02217); and one G3 strain, UVE/JEV/UNK/TW/
RP9-190 (1.2 x107 RNA copies/μl; GenBank KF907505, EVA 001V-02344) [16]. Other Flavivi-
rus RNAs from the JEV complex: two WNV strains, UVE/WNV/1999/US/NY 385–99 (103.57
TCDI50/mL, GenBank AY842931, EVA 001v-EVA140) and UVE/WNV/UNK/CF/Ar B 3573/
82 (104.07 TCID50/mL, GenBank DQ318020, EVA 001v-EVA91), and one SLEV strain: UVE/
SLEV/UNK/US/MSI-7 (104.82 TCID50/mL, GenBank DQ359217, EVA 001v-EVA128). Serial
1:10 dilutions of each RNA were prepared using AVE buffer containing RNA carrier (Qiagen,
UK) [43]. Working aliquots were frozen at -20˚ C to avoid repeat freeze-thawing. JEV RNA
dilutions were selected to cover a wide range of concentrations from positive to negative for all
assays and conditions tested. For other Flaviviruses RNA, 10−5 dilution was chosen because it
represented a moderate Cq value of approximately 30 cycles in WNV and SLEV specific qPCR
assays.
Technical development of RT-qPCR assays
Comparison of RT-qPCR conditions using the pre-existing in-house system. Different
factors were evaluated following step-by-step variation using the pre-existing in-house assay
with dilutions of JEV G1-1326 RNA. Factors tested included: 1) Mastermix: EXPRESS One-
Step SuperScript1 qRT-PCR ‘Express kit’ (Thermo Fisher, UK), SuperScript™ III One-Step
RT-PCR System with Platinum™ Taq DNA Polymerase ‘Superscript-III kit’ (Thermo Fisher,
UK) and TaqMan1 Fast Virus 1-Step ‘Fastvirus kit’ (Thermo Fisher, UK), according to man-
ufacturers’ instructions, see standard reaction mix preparation and cycling conditions in
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Table 1; 2) Reaction volumes (25 vs 50μL); 3) Sample volumes (5–16μL), see Table 2. All RT-
qPCR assays for optimisation and subsequent experiments were run using a CFX96TM qPCR
detection system (Biorad laboratories). Cq> 40 were reported as negative, and40 as
positive.
Selection of the best performing RT-qPCR systems. The ten different systems were
compared by testing them on 7 tenfold dilutions of JEV G1-1326 RNA in duplicate, and G3
RP9-190 RNA tested once, using ‘Superscript-III kit’ following standard conditions, see
Table 1. On the basis of these results, the three RT-qPCR systems with the lowest limit of
detection (LOD), i.e. highest dilution found positive for all replicates, were selected for
optimisation.
Assay optimisation. The three selected RT-qPCR assays were performed on dilutions of
JEV G1-1326 RNA in duplicate using ‘Superscript-III kit’ and step-by-step optimisation of
Table 1. Standard reaction mixes and cycling conditions.
Mastermix Preparation Cycling Conditions
Superscript-III kit
SuperScript™ III One-Step RT-PCR System with
Platinum™ Taq DNA Polymerase
Total Reaction volume
25 μL:
1) x2 Mastermix 12.5 μL
2) Forward and reverse
primers 400nM
3) Probe 160nM
4) Enzyme 0.5 μL
5) JEV RNA 5 μL
50˚C for 15 minutes
95˚C for 2 minutes
X 45 (95˚C for 15 seconds
+ 60˚C for 45 seconds)
Express kit
EXPRESS One-Step SuperScript1 qRT-PCR
Total Reaction volume
20 μL:
1) x2 Mastermix 10 μL
2) Forward and reverse
primers 400nM
3) Probe 160nM
4) Enzyme 2 μL
5) JEV RNA 5 μL
50˚C for 15 minutes
95˚C for 2 minutes
45 x (95˚C for 15 seconds
+ 60˚C for 45 seconds)
Fastvirus kit
TaqMan1 Fast Virus 1-Step
Total Reaction volume
25 μL:
1) X4 Mastermix 6.25 μL
2) Forward and reverse
primers 400nM
3) Probe 160nM
4) JEV RNA 5 μL
50˚C for 5 minutes
95˚C for 20 seconds
45 x (95˚C for 15 seconds
+ 60˚C for 60 seconds)
https://doi.org/10.1371/journal.pone.0194412.t001
Table 2. Comparison of RT-qPCR conditions using the pre-existing in-house RT-qPCR assay.
Factor Mastermix# Sample volume Reaction volume Annealing temperature Primer concentration Probe concentration












III Sample volume Superscript-III 1. 10μl
2. 16μl
50μl 60˚C 400nM 160nM
Fastvirus 1. 5μl
2. 15μl
25μl 60˚C 400nM 160nM
 All experiments were performed with G1-1326 RNA tenfold dilutions.
#Superscript-III kit: SuperScript™ III One-Step RT-PCR System with Platinum™ Taq DNA Polymerase; Express kit: EXPRESS One-Step SuperScript1 qRT-PCR and
Fastvirus kit: TaqMan1 Fast Virus 1-Step.
https://doi.org/10.1371/journal.pone.0194412.t002
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various conditions, involving 1) annealing temperatures 54–64˚C, 2) primer concentration
(200-800nM), and 3) probe concentration (100-400nM), see Table 3.
Validation
For the three selected RT-qPCR assays, efficiency, repeatability and LOD, were assessed using
optimised RT-qPCR assay protocols (based on results of 2.4.1 and 2.4.3) using JEV G1-769 or
JEV G3- RP9-190 RNA dilutions (10−3 to 10−10) in triplicate, and repeated on two different
days. Cross-reaction of the assays were tested using RNA from viruses in the JEV serocomplex
at 10−5 dilutions: two WNV strains and one SLEV strain.
Evaluation using patient samples with Central Nervous System (CNS)
infections
Two groups of consecutive patients with CNS infection, admitted 2009–2015, were retrospec-
tively tested: group 1 with acute encephalitis syndrome determined using the clinical WHO
criteria [44] and admitted within 7 days of fever onset to Mahosot Hospital; and group 2 with
suspected CNS infection from three other hospitals in Vientiane, the Friendship, Children and
Setthathirat Hospitals. CSF was collected by lumbar puncture (LP) from consenting patients
without contraindications to LP, according to the judgment of the responsible physician.
Blood was collected on admission for all patients. Samples were sent to the Mahosot Hospital
Microbiology Laboratory. CSF and serum, after blood centrifugation, were aliquoted and
stored at -80˚C.
200 μl serum and CSF samples were extracted and eluted in 60μl on a EZ1 Advanced
machine using EZ1 Virus Mini Kit v2.0 (Qiagen, UK) following manufacturer’s instructions.
The validated JEV RT-qPCR assays were performed as per the optimised protocols for each
sample. Positive and negative (no template) controls were performed for each RT-qPCR run.
An internal control (MS2 phage) was added to each patient sample. After extraction, MS2 RT-
qPCR was performed to control the extraction process and to exclude inhibition as previously
described [45].
Sequencing
Single positive RT-qPCR results were further investigated by sending the RT-qPCR product
for next-generation sequencing using Ion S5 system (Thermo Fisher, Waltham, USA), to
Unite´ des Virus Emergents, Faculty of Medicine, Marseille, France.
Table 3. Optimisation experiments performed for the three best performing RT-qPCR systems.





5μl 25μl 54, 56, 58, 60, 62 and
64˚C
400nM 200nM
II Primer concentration Superscript-
III
5μl 25μl 1. 60˚C
2. 62˚C
3. 56˚C
200, 300, 400, 500, 600 and 800
nM
200nM
III Probe concentration Superscript-
III
5μl 25μl 1. 60˚C
2. 62˚C
3. 56˚C
600nM 100, 200, 300 and
400nM
 All experiments were performed with G1-1326 tenfold dilutions.
#Annealing temperature for the Pyke, NS2A and NS3 systems were 60, 62 and 56˚C respectively.
https://doi.org/10.1371/journal.pone.0194412.t003
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Pan-flavivirus RT-PCR
The standard diagnostic algorithm at Mahosot Hospital did not include a JEV RT-PCR assay,
but it did include prospective testing using a pan-flavivirus hemi-nested SybrGreen RT-qPCR
with sequencing for identification. This was performed as per a published protocol [46], with
results presented alongside JEV RT-qPCR results.
Panbio ELISA
Detection of anti-JEV IgM using JEV MAC-ELISA is the World Health Organisation recom-
mended test for diagnosing JEV infection. Japanese Encephalitis-Dengue IgM Combo ELISA
kit (Catalogue number E-JED01C; Panbio ELISA; Inverness Medical Innovations, Brisbane,
Australia, formerly Panbio Ltd) is a commercial JEV MAC-ELISA kit that is combined with an
anti-Dengue IgM test to exclude cross-reactivity. The test was performed according to the
manufacturers’ instructions, reported as anti-JEV or anti-Dengue IgM Positive, Equivocal or
Negative [22]. For the purposes of this analysis, anti-Dengue IgM Positive or Equivocal, or
anti-JEV IgM Equivocal were interpreted as anti-JEV IgM Negative.
Ethical considerations
The study was part of an ongoing study on the causes of CNS infections in Laos. Ethical clear-
ance was granted by the Ethical Review Committee of the Faculty of Medical Sciences,
National University of Laos, and the Oxford University Tropical Ethics Research Committee,
Oxford, UK. Diagnostic testing was performed on anonymised and frozen serum and CSF
samples previously collected. Venepuncture and LPs were performed if written consent was
given by patients or their parents/guardian.
Results
Systematic review and bioinformatics analysis
Forty-six studies evaluating JEV RT-PCR assays were identified (see S1 File, S1 Fig and
Table A in S2 File), including 7 assays utilising hydrolysis probes [27, 47–52]. The first pub-
lished record of JEV RT-PCR was performed as a conventional RT-PCR at the National Insti-
tute of Health, Maryland, USA, in 1991 [53]. Since then, a variety of techniques have been
harnessed: conventional and nested RT-PCR; and RT-qPCR using hydrolysis probes or SYBR
green. Genotype-specific assays have also been reported, specifically for G1 and G3 [52, 54].
Thirteen (28%) studies reported detection of JEV RNA in patients (see Table A in S2 File).
Among these studies, the median number of published JEV cases confirmed by the assay was
12 (range 1–75). These mainly involved CSF samples, but the assays also detected JEV RNA in
serum. A case report has recently demonstrated detection of JEV RNA in urine, although this
was not substantiated by a larger case series of 52 JEV patients [55, 56].
The primers and probes from the five published hydrolysis probe RT-qPCR assays specifically
designed for detection of JEV RNA in human cases (Table C in S2 File) were aligned with the 303
complete genome sequence (see Table B in S2 File for Accession numbers, Table D in S2 File for
sequence alignment). Pyke et al, Yang et al and Shirato et al [27, 48, 50] systems showed the best
fit with the sequence alignment in-silico, with published validation data including genotypes
tested, and were chosen for subsequent analysis. Six new primer/probe sets were also designed,
targeting conserved regions of 1) all Genotypes, 2) G1 and G3 (Table 4). It is notable that the G1
and G3 assays were designed using two separate multiple genome alignments containing only
strains belonging to the corresponding genotype. However, they were not exclusively targeting a
specific genotype, and for this reason the assays were tested against both G1 and G3.
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Technical development of RT-qPCR assays
Comparison of RT-qPCR conditions using the pre-existing in-house system. Experi-
ments were performed to establish the best mastermix kits, reaction and sample volumes using
the pre-existing in-house system. All the possible combinations were not performed, but the
kits were evaluated with 5 tenfold dilutions of G1-1326 RNA in duplicate or triplicate to ade-
quately compare the limits of detection.
Table 4. Primers and probes evaluated during the study.
Author Target (nt) Oligonucleotides Sequence (5’-3’) Tm (˚C)
Pre-existing in-house NS3 (103) Forward 6399-TYG-AYG-CRA-GRG-TTT-ATG-CAG 61–68
Probe 1 Fam-AGT-GGT-TTA-AGG-ATT-TTG-CAG-C-Tamra 62
Probe 2 Fam-AGT-GGT-TCA-ARG-ACT-TTG-CAG-C-Tamra 64–66
Reverse 6502-CAT-RCG-ACC-GAG-CAC-CTC-TA 64–67
Pyke et al 2004 NS5 (62) Forward 10230-ATC-TGG-TGY-GGY-AGT-CTC-A 61–67
Probe Fam-CGG-AAC-GCG-ATC-CAG-GGC-AA-Tamra 69
Reverse 10292-CGC-GTA-GAT-GTT-CTC-AGC-CC 65
Yang et al 2004 3’ UTR (146) Forward 10764-GGT-GTA-AGG-ACT-AGA-GGT-TAG-AGG 64
Probe Fam-CCC-GTG-GAA-ACA-ACA-TCA-TGC-GGC-Tamra 70
Reverse 10910-ATT-CCC-AGG-TGT-CAA-TAT-GCT-GTT 66
Shirato et al 2005 5’ UTR (75) Forward 80-AGA-ACG-GAA-GAY-AAC-CAT-GAC-TAA-A 64–66
Probe Fam-ACC-AGG-AGG-GCC-CGG-MGB NFQ 81
Reverse 155-CCG-CGT-TTC-AGC-ATA-TTG-AT 62
New (this study)
NS2A (all Genotypes)–v1 NS2A (116) Forward 3563-AGC-TGG-GCC-TTC-TGG-T 64
Probe Fam-CTT-CGC-AAG-AGG-TGG-ACG-GCC-A-Tamra 70
Reverse 3675-CCC-AAG-CAT-CAG-CAC-AAG 62
NS2A)–v2 NS2A (112) Forward 3563-AGC-TGG-GCC-TTC-TGG-T 64
Probe Fam- TGG-CCG-TCC-ACC-TCT-TGC-GAA-G -Tamra 70
Reverse 3675-CCC-AAG-CAT-CAG-CAC-AAG 62
NS5 (G 1)–v1 NS5 (315) Forward 9925-GDG-CTG-GAT-GGA-ATG-TGA 61–63
Probe Fam-AGG-AGA-GTG-GAT-GAC-CAC-MGB NFQ 75
Reverse 10240-CCA-CAC-CAG-ATG-TCC-TC 60
NS5 (G 1)–v2 NS5 (315) Forward 9925-GDG-CTG-GAT-GGA-ATG-TGA 61–63
Probe Fam-AGG-AGA-GTG-GAT-GAC-YAC-MGB NFQ 72–76
Reverse 10240-CCA-CAC-CAG-ATG-TCC-TC 60
NS3 (G 3)–v1 NS3 (141) Forward 5726-GCA-ATG-TGC-CTC-CAA-AGA-GC 65
Probe Fam-TCC-TAT-GAY-ACA-GAA-TAY-CCA-AA-MGB NFQ 73–78
Reverse 5884-GTC-GAT-GAC-CCT-GCT-CGC 66
NS3 (G 3)–v2 NS3 (158) Forward 5726-GCA-ATG-TGY-CTC-CAA-AGA-GC 63–66
Probe Fam-TCC-TAT-GAY-ACA-GAA-TAY-CCA-AA-MGB NFQ 73–78
Reverse 5884-GTC-GAT-GAC-CCT-GCT-CGC 66
Position of the oligonucleotides is related to the Nakayama strain, Accession number EF571853.
Tm: melting temperature calculated using IDTNA tool https://www.idtdna.com/calc/analyzer setting parameters as follows: Target type RNA, Oligo Conc 0.4μM, Na
Conc 50mM, Mg Conc 3mM, dNTPs Conc 0.8mM. Tms for MGB (minor groove binder) probes include an additional 15˚C.
A more extensive list of all oligonucleotides evaluated in-silico is included in Table C in S2 File.
NS2Av2 was designed as NS2Av1 with a modification of the probe sequence as its reverse complement.
NS5v2 was designed as NS5v1 with a modification of the probe sequence, with a degeneracy Y inserted instead of C at position 16.
NS3v2 was designed as NS3v1 with a modification of the forward primer sequence, with a degeneracy Y inserted instead of C at position 9.
NS = gene coding for non-structural protein. G = genotype
https://doi.org/10.1371/journal.pone.0194412.t004
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Mastermix. Three kits were compared, Superscript-III kit, Express kit and Fastvirus kit.
The LOD for Superscript-III kit and Fastvirus kit was 10−6, as compared to 10−5 for Express kit
(Table E in S2 File). The Express kit was not therefore used in further experiments.
Reaction volumes (25μl vs 50μl). The manufacturers’ instructions for both Superscript-
III and Fastvirus kits advise performing RT-qPCR as 50μl reaction volumes. In an effort to
conserve reagents, only Superscript-III kit was used to compare two reaction volumes, 25μl
and 50μl. Increasing the reaction volume from 25μl to 50μl resulted in a lower LOD, 10−6 vs
10−7 (Table E in S2 File).
Sample volumes. The standard sample volume was 5μl. As suggested by the kit manufac-
turer, the sample volume may be increased by not adding water in the reaction mix. For Super-
script-III kit, the sample volume may be increased to 8μl in a 25μl reaction volume, equivalent
to 16μl in a 50μl reaction volume. For Fastvirus kit the sample volume may be increased to
15μl in a 25μl reaction volume, vs. 30μl in a 50μl reaction volume. The results demonstrate a
lower LOD (10−7 vs. 10−6) with a larger sample volume (Table E in S2 File).
The experiments thus demonstrated that the optimal conditions involved use of the Fas-
tvirus kit with a 30μl sample volume and 50μl reaction volume. These optimised conditions
were subsequently used for the validation experiments described in Section 3.3.
Selection of the best performing RT-qPCR systems. A total of ten RT-qPCR systems,
the pre-existing in-house, three published systems, and six (two versions each of three) newly
designed systems, were tested on JEV G1-1326 RNA in duplicate, and G3 RP9-190 RNA once,
in tenfold serial dilutions using Superscript-III under standard conditions. RT-qPCR results
are presented in Table F in S2 File. Three RT-qPCR systems with the lowest LOD were selected
for further optimisation: two pan-genotype assays, the Pyke and NS2A version 1 (subsequently
called NS2A); and a G3 assay, NS3 version 2 (subsequently called NS3).
Assay optimisation. The Tm, primer and probe concentrations were optimised using
Superscript-III under standard reaction and sample volumes.
The performance of the three selected assays at different annealing temperatures from 52 to
64˚C was assessed by testing JEV G1-1326 RNA in triplicate in tenfold serial dilutions. A
three-step protocol was used for the cycling: 1) denaturation 95˚C for 0:15, 2) annealing x˚C
for 0:30, and then 3) extension 68˚C for 0:30. Adjusting the annealing temperature of the ther-
mocycling protocol improved the LOD by one log10 for two assays, Cq results presented in
Table G in S2 File. The optimal annealing temperature for the Pyke assay was 60˚C, NS2A
assay was 62˚C and NS3 assay was 56˚C (Table G in S2 File).
The assays were tested in duplicate at various combinations of forward and reverse primers
concentrations, from 200-600nM, using G1-1326 RNA at 10−6, results presented in Table H in
S2 File. There was minimal difference between Cq results, and a concentration of 600nM for
both forward and reverse primers were selected for further experiments.
The assays were tested at different probe concentrations, from 100-400nM, using G1-1326
RNA in duplicate at 10−6, results presented in Table I in S2 File. 300nM was selected for further
experiments.
Note that Cq values in Tables H and Table I in S2 File are not directly comparable to each
other because different PCR runs employed different threshold settings.
Validation. In view of the results detailed above, the final conditions employed Fastvirus
kit with a reaction volume of 50μL, sample volume of 30μl, and primer and probe concentra-
tions of 600nM and 300nM, respectively. The optimal annealing temperature was different for
each assay: 60˚C, 62˚C and 56˚C for the Pyke, NS2A and NS3 assays, respectively. This was
performed as a two-step protocol, as per the Fastvirus manufacturer’s instructions.
RT-qPCR was performed with serial RNA dilutions in triplicate on 2 different days, for the
Pyke and the NS2A assays using G1-769 10−3 to 10−10 or for NS3 (G3 assay) with G3-RP-190
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10−4 to 10−11. The standard curves are shown in Fig 1 with Cq results in Table 5. The limit of
detection (LOD) for the Pyke assay was 1.3 JEV RNA copies/μl or 39 copies/reaction, for the
NS2A assay was 1.3x10-1 JEV RNA copies/μl or ~4 copies/reaction and for the NS3 assay was
1.2 x10-1 JEV RNA copies/μl or ~4 copies/reaction. Similar results were obtained when testing
NS2A on G3-RP9-190, see Table 5.
Efficiency was calculated from the standard curve for Day 1 and 2: 101.3% and 105.2% for
the Pyke; 95.1% and 101.2% for NS2A; and 107.5% and 110.2% for NS3 (Fig 1). Assay repeat-
ability was assessed by calculating the standard deviation (SD) for the Cq variance, presented
in Table 5. SD for all assays was less than 0.40, excluding the dilution at the LOD, suggesting
adequate repeatability of the assays.
No amplification was detected in testing the assays with WNV or SLEV.
Fig 1. Standard curves of the 1) Pyke, 2) NS2A assays and 3) NS3 assays with G3-RP9-190 on (A) Day 1 and repeated
on (B) Day 2. Result of the RT-qPCR run, ‘Cq’, is plotted against the ‘log starting copies number’, at the RNA dilutions
detected: Pyke assay 1:10 serial dilutions of G1-769 in triplicate at 10−3 to 10−6; NS2A assay 1:10 serial dilutions of G1-
769 in triplicate at 10−3 to 10−7; and NS3 with G3-RP-190 10−4 to 10−7. Efficiency = 10−1/slope-1. R2 = Correlation
Coefficient. RT-qPCR performed with Fastvirus kit (TaqMan1 Fast Virus 1-Step) with a reaction volume of 50μL,
sample volume of 30μl, and primer and probe concentrations of 600nM and 300nM respectively. Thermocycling
conditions were 50˚C for 5 minutes, 95˚C for 20 seconds and 45 x (95˚C for 15 seconds + x˚C for 60 seconds). The
optimal annealing temperature ‘x˚C’ was different for each assay: 62˚C, 60˚C and 56˚C for the Pyke, NS2A and NS3
assays respectively.
https://doi.org/10.1371/journal.pone.0194412.g001
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Evaluation using patient samples with Central Nervous System (CNS)
infections
123 patients were tested with the three optimised RT-qPCR assays (conditions as described in
Section 3.2.1), 58 patients from group 1 (2011–2014) and 65 from group 2 (2008–2015),
including a total of 95 serum and 120 CSF samples. 35.8% (44/123) of the patients were found
anti-JEV IgM positive by MAC ELISA. Positive RT-qPCR results are presented in Table 6,
alongside results for JEV MAC-ELISA, hemi-nested panflavivirus RT-qPCR and RT-qPCR
sequencing results. None of the samples were considered inhibitory according to the results of
MS2 testing. Two patients (2 CSF samples) were positive using the NS2A assay, of which 1 (1
CSF) was also positive by the NS3 assay. These 2 patients were known positives by cell inocula-
tion and/or hemi-nested panflavivirus assay. 12 (8 CSF and 4 serum samples) were positive by
the Pyke assay alone. As 11/12 (92%) of these patients were not previously detected by the pan-
flavivirus assay or cell inoculation, the RT-qPCR products were sent for sequencing. This
revealed that the amplicons generated by the Pyke assay with these clinical samples consisted
of primer multimers and primer/probe concatemers resulting from non-specific amplification,
possibly related to the unusually high GC content at 3’ end of the reverse primer, GCCC.
Discussion
This systematic review confirmed that the detection of JEV RNA in suspected human cases by
RT-PCR is uncommon. Forty-six studies were identified, involving a variety of RT-PCR tech-
niques, however only a quarter had any published record of detection of JEV RNA in human sam-
ples. It was common for an article title to poorly identify the study as evaluating a JEV RT-PCR
method, and while every effort was made to hand-search publications, it is possible that the search
was not 100% comprehensive. Additionally, studies utilising the assays may not have cited them.
Articles rarely adhered to the MIQE guidelines for evaluation of RT-PCR methods, such as
reporting accession numbers of JEV strains used or details of the optimisation process [39].
Many were only optimised and validated on G3, whereas G1 is now the predominant strain. It
is also important to differentiate studies developing RT-qPCR for detection in mosquitos as
opposed to humans, as they are not consistently interchangeable. Mosquito surveillance may
require a cost-effective and rapid method, but in clinical diagnostics analytical accuracy is of
utmost important. To this end, a number of studies detecting JEV RNA in clinical samples
incorporated nested RT-PCR methods. Although nested RT-PCR may improve both analytical
sensitivity and specificity, it is cumbersome and prone to cross-contamination. In the study by
Meiyu et al [57], it was reported that out of 52 clinical JEV cases, an extraordinary 45 (87%)
were PCR positive for JEV RNA. However, there was no additional evidence to support the
diagnosis, such as repeat testing, sequencing of the isolates or alternative confirmation. Exist-
ing RT-qPCR assays detect JEV RNA in 0–25% of clinical cases.
It is for these reasons that we focussed on identifying and validating the most effective RT-
qPCR assay. Hydrolysis probe assays are the most extensively used methods for nucleic acid
detection, both for clinical and research diagnostic purposes. From the results of the systematic
review, 3 published systems incorporating hydrolysis probes were selected on the basis of best
matching in silico. Assessment with JEV RNA dilutions of G1 and G3 showed the lowest LOD
was obtained with the Pyke system: 2 logfold below both the Yang and Shirato assays with G1,
and 1 logfold below both with G3 [27, 50]. It is recognised that the conditions employed were
not identical to those published, and it would have been interesting to compare the validated
assays with existing assays performed with published conditions. Validation experiments con-
firmed good RT-qPCR efficiency and LOD of 1.3 JEV RNA copies/μl or 39 copies/reaction.
However, in a study of patient samples with paired serum and CSF, all the positive RT-qPCR
Optimised reverse-transcription PCR (RT-qPCR) for detection of Japanese Encephalitis Virus (JEV)
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products that were sequenced, even results with Cq of approximately 30 showed non-specific
amplification. Eleven positive samples were detected by the Pyke assay alone, of which all were
sequenced and showed non-specific amplification.
The results highlight the importance of validating a newly designed RT-qPCR method
against a panel of negative patients samples in addition to the no-template controls recom-
mended by the MIQE guidelines [39]. The oligonucleotides tested in these experiments had
been checked in-silico for specificity, and also experimentally tested for cross-reactivity against
strains of the closely related viruses, WNV and SLE. All the experiments had been performed
with at least one no template control per RT-qPCR plate. Nonetheless, the results of validation
against patient CSF and serum samples suggested poor specificity of the Pyke assay. It is possi-
ble that further optimisation, increasing the annealing temperature and reducing the primer
concentrations may have improved the specificity, although this may adversely affect sensitiv-
ity of the assay.
The new assays aimed to improve the sensitivity of detection, through targeting various
conserved regions from a multiple genome alignment. The NS2A region was chosen for the
pan-genotype assay, and NS5 and NS3 for the G1 and G3 systems, respectively. Two versions
of each system were designed. An initial assessment showed poor performance of the NS5
assay, and this was not used in further experiments. Initial optimisation experiments demon-
strated best results with Fastvirus mix, with the maximal reaction and sample volumes
(although it is recognised that use of 30 μL of extract for a single assay may not be consistently
possible in practice). The assays were individually optimised for annealing temperature,
primer and probe concentrations. Validation showed one logfold lower LOD for the NS2A
compared to the published Pyke assay for G1, NS2A assay was 1.3x10-1 JEV RNA copies/μl or
~4 copies/reaction. NS2A and NS3 showed equally good results for G3, with LOD 1.2 x10-1
JEV RNA copies/μl or ~4 copies/reaction. Individual assays targeting highly conserved regions
of G1 and G3 did not improve the sensitivity of diagnosis. Nonetheless, it may be useful to tar-
get multiple regions of the viral genome to overcome false negatives due to mutations in any
single region.
A study of patient samples, including paired serum and CSF, demonstrated marginally
improved detection of JEV RNA as compared to the existing hemi-nested panflavivirus RT-
qPCR assay. One case was detected with the hemi-nested RT-qPCR assay, and both this and
an additional case were detected by the new assays. The low number of positives is consistent
with previous data. It must also be taken into account that this involved retrospective testing
using samples stored for many years. The potential greater sensitivity of the NS2A as compared
to the NS3 is likely due to both JEV strains detected established previously by sequencing as
G1.
In conclusion, the novel pan-genotype NS2A assay and G3 NS3 assay described here
showed higher analytical sensitivity than previously described RT-qPCR assays for JEV RNA.
However, it will be essential to field-test them in serum, CSF and other body fluids, to evaluate
their sensitivity and potential for improved diagnostic capacity in a large prospective study.
Since our systematic review, there have been no further JEV specific diagnostic assays pub-
lished, but there has been evidence of the potential for improved detection of JEV RNA in
other body fluids, whole blood [56], throat swabs (Bharucha et al, submitted) and urine sam-
ples [56, 58], and this needs further evaluation.
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